Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2


Posted: 2021-10-30 19:00:00
J Am Soc Nephrol . 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672. Constantin J Thieme 1 , Arturo Blazquez-Navarro 1 2 , Lema Safi 2 , Sviatlana Kaliszczyk 2 , Krystallenia Paniskaki 3 , Isabel E Neumann 1 , Kita Schmidt 1 , Mara Stockhausen 2 , Jan Hörstrup 4 , Ocan Cinkilic 5 , Linus Flitsch-Kiefner 6 , Toni L Meister 7 , Corinna Marheinecke 7 , Stephanie Pfaender 7 , Eike Steinmann 7 , Felix S Seibert 2 , Ulrik Stervbo 2 , Timm H Westhoff 2 , Toralf Roch 1 2 , Nina Babel 8 2 Affiliations Expand Affiliations 1 Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. 2 Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany. 3 Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 4 Kuratorium für Dialyse und Nierentransplantat, Berlin, Germany. 5 Dialyse Schwerte, Schwerte, Germany. 6 Kuratorium für Dialyse und Nierentransplantat, Hagen, Germany. 7 Department of Molecular and Medical Virology, Ruhr University, Bochum, Germany. 8 Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany nina.babel@elisabethgruppe.de. Item in Clipboard Constantin J Thieme et al. J Am Soc Nephrol. 2021 Nov. Show details Display options Display options Format J Am Soc Nephrol . 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672. Authors Constantin J Thieme 1 , Arturo Blazquez-Navarro 1 2 , Lema Safi 2 , Sviatlana Kaliszczyk 2 , Krystallenia Paniskaki 3 , Isabel E Neumann 1 , Kita Schmidt 1 , Mara Stockhausen 2 , Jan Hörstrup 4 , Ocan Cinkilic 5 , Linus Flitsch-Kiefner 6 , Toni L Meister 7 , Corinna Marheinecke 7 , Stephanie Pfaender 7 , Eike Steinmann 7 , Felix S Seibert 2 , Ulrik Stervbo 2 , Timm H Westhoff 2 , Toralf Roch 1 2 , Nina Babel 8 2 Affiliations 1 Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. 2 Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany. 3 Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 4 Kuratorium für Dialyse und Nierentransplantat, Berlin, Germany. 5 Dialyse Schwerte, Schwerte, Germany. 6 Kuratorium für Dialyse und Nierentransplantat, Hagen, Germany. 7 Department of Molecular and Medical Virology, Ruhr University, Bochum, Germany. 8 Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany nina.babel@elisabethgruppe.de. Item in Clipboard CiteDisplay options Display options Format No abstract available Keywords: COVID-19; SARS-CoV-2; cellular; chronic hemodialysis; clinical immunology; immunity; infectious diseases; kidney disease; mRNA vaccine; vaccination. Publication types

参考サイト PubMed: covid-19


Powered by Vergleichsportal


バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
5月 08, 2020 バイオアソシエイツ

CytoDyn社、COVID-19薬のレロンリマブについて更新。 初期の結果は、Gilead社のレムデシビルに対する明確な優位性を示唆。(プレゼン全容)

レロンリマブ要約:- COVID-19 の三拍子揃った薬-レロンリマブはサイトカインストームを静め、免疫学的ホメオスタシスを回復し、ウイルス量を減らす-Gileadの抗ウイルス薬レムデシビルとGenetechの抗IL-6…

ゲスト 536人 と メンバー 6人 がオンラインです